There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Codexis (CDXS – Research Report), Leap Therapeutics (LPTX – Research Report) and Sutro Biopharma (STRO – Research Report) with bullish sentiments.
Codexis (CDXS)
Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Codexis on January 17 and set a price target of $9.00. The company’s shares closed last Monday at $2.77.
According to TipRanks.com, Hewitt is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Codexis is a Moderate Buy with an average price target of $6.75, which is a 148.2% upside from current levels. In a report issued on January 18, Piper Sandler also maintained a Buy rating on the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Leap Therapeutics (LPTX)
In a report issued on January 17, Joseph Catanzaro from Piper Sandler assigned a Buy rating to Leap Therapeutics, with a price target of $21.00. The company’s shares closed last Monday at $3.07.
According to TipRanks.com, Catanzaro is a 4-star analyst with an average return of
Currently, the analyst consensus on Leap Therapeutics is a Strong Buy with an average price target of $12.75, representing a 297.2% upside. In a report issued on January 2, Mizuho Securities also maintained a Buy rating on the stock with a $12.00 price target.
Sutro Biopharma (STRO)
Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Sutro Biopharma on January 17 and set a price target of $12.00. The company’s shares closed last Monday at $4.42.
According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of
Sutro Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $12.50, implying a 208.6% upside from current levels. In a report issued on January 5, H.C. Wainwright also maintained a Buy rating on the stock with a $16.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CDXS:
- Codexis price target raised to $3 from $2 at TD Cowen
- Codexis enters into purchase agreement with Nestle Health Science for CDX-7108
- Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
- Codexis enters into pruchase agreement with Nestle Health Science for CDX-7108
- Codexis and Aldevron in licensing pact for Codex HiCap RNA Polymerase
